Andrew Wylie

Andrew Wylie has over 16 years of oncology drug discovery experience in both small biotech and big pharma environments. Prior to joining KSQ Therapeutics, Andrew served as a Director in the Oncology group at the Novartis Institutes for BioMedical Research where he was responsible for leading drug discovery teams from early conceptual stages to the nomination of clinical candidates. In this role, Andrew led internal and external teams that identified and progressed a number of important oncology programs from lead optimization through IND-enabling studies including Asciminib (ABLOOI), the first allosteric inhibitor targeting BCR-ABL and LXS196 a PKC inhibitor in development for uveal melanoma. Prior to joining Novartis, Andrew held oncology drug discovery roles of increasing responsibility at Infinity Pharmaceuticals and Vertex.

Andrew earned his PhD in Genetics from the University of Glasgow, Scotland, and was an AstraZeneca postdoctoral fellow based in Duke University, North Carolina, USA. He has authored several patents and published in top-tier scientific journals.